|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
We also found no evidence for a significant association of rs10046 genotypes with breast cancer prognosis.
|
29363090 |
2018 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We also found no evidence for a significant association of rs10046 genotypes with breast cancer prognosis.
|
29363090 |
2018 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Homozygotes of minor alleles of CYP19 rs10046 (CC) were associated with a reduced risk of BC with OR: 0.61 (95%CI = 0.39-0.95).
|
27323034 |
2016 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
A significant association was observed between the rs10046 polymorphism of the CYP19gene and breast cancer in Iranian patients.
|
27165202 |
2016 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
A significant association was observed between the rs10046 polymorphism of the CYP19gene and breast cancer in Iranian patients.
|
27165202 |
2016 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Homozygotes of minor alleles of CYP19 rs10046 (CC) were associated with a reduced risk of BC with OR: 0.61 (95%CI = 0.39-0.95).
|
27323034 |
2016 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, breast cancer in Xinjiang Uigur women is closely connected with the age, BMI, parity, abortion, and CYP19 rs10046 polymorphisms.
|
26345775 |
2015 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, breast cancer in Xinjiang Uigur women is closely connected with the age, BMI, parity, abortion, and CYP19 rs10046 polymorphisms.
|
26345775 |
2015 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
No rs10046 genotypes were significantly associated with increased breast cancer risk or patient character</span>istics other than age at onset.
|
24402127 |
2014 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
No rs10046 genotypes were significantly associated with increased breast cancer risk or patient character</span>istics other than age at onset.
|
24402127 |
2014 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We can conclude that the rs10046 polymorphism on CYP19 by itself does not constitute breast cancer risk.
|
23342035 |
2013 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
We can conclude that the rs10046 polymorphism on CYP19 by itself does not constitute breast cancer risk.
|
23342035 |
2013 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
We did not observe an association between potential functional genetic polymorphisms in the estrogen pathway, SHBG rs6259, ESR1 rs2234693, CYP19 rs10046 and rs4775936, and UGT1A1 rs8175347, or the progesterone pathway, PGR rs1042838, with the risk of breast cancer.
|
23935996 |
2013 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We did not observe an association between potential functional genetic polymorphisms in the estrogen pathway, SHBG rs6259, ESR1 rs2234693, CYP19 rs10046 and rs4775936, and UGT1A1 rs8175347, or the progesterone pathway, PGR rs1042838, with the risk of breast cancer.
|
23935996 |
2013 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
A common haplotype composed of the Val(80) G allele and three haplotype-tagging single nucleotide polymorphisms (rs727479, rs10046, and rs4646) in the CYP19 coding region showed a trend to association with breast cancer risk in BRCA1 carriers ages <50 years.
|
19366906 |
2009 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
A common haplotype composed of the Val(80) G allele and three haplotype-tagging single nucleotide polymorphisms (rs727479, rs10046, and rs4646) in the CYP19 coding region showed a trend to association with breast cancer risk in BRCA1 carriers ages <50 years.
|
19366906 |
2009 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study provides evidence that polymorphisms CYP17 rs743572, CYP19 rs10046 and ER-alpha rs3798577 are associated with breast cancer risk among Chinese women.
|
18629629 |
2009 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study provides evidence that polymorphisms CYP17 rs743572, CYP19 rs10046 and ER-alpha rs3798577 are associated with breast cancer risk among Chinese women.
|
18629629 |
2009 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
In a case-control study nested within a breast self-examination trial conducted in China, we examined whether CYP19A1 polymorphisms (rs1870049, rs1004982, rs28566535, rs936306, rs11636639, rs767199, rs4775936, rs11575899, rs10046, and rs4646) were associated with risk of breast cancer and fibrocystic breast conditions.
|
19064562 |
2008 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In a case-control study nested within a breast self-examination trial conducted in China, we examined whether CYP19A1 polymorphisms (rs1870049, rs1004982, rs28566535, rs936306, rs11636639, rs767199, rs4775936, rs11575899, rs10046, and rs4646) were associated with risk of breast cancer and fibrocystic breast conditions.
|
19064562 |
2008 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
SNPs rs10046 and rs4646 may influence the HER2 status of breast cancer tumors, and rs10046 genotypes are associated with an altered DFS.
|
18049890 |
2008 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
SNPs rs10046 and rs4646 may influence the HER2 status of breast cancer tumors, and rs10046 genotypes are associated with an altered DFS.
|
18049890 |
2008 |
|
Endometriosis
|
|
0.030 |
GeneticVariation
|
BEFREE |
Present meta-analysis reveals that CYP19 rs10046 polymorphism may be not correlated to endometriosis risk.
|
26897397 |
2016 |
|
Endometriosis
|
|
0.030 |
GeneticVariation
|
BEFREE |
We assessed the CYP17 5'-untranslated region -34 A/G (rs743572) and CYP19 Ex10 + C1558T (rs10046) SNPs in stage I-II endometriosis.
|
23809139 |
2013 |
|
Endometriosis
|
|
0.030 |
GeneticVariation
|
BEFREE |
Patients with endometriosis (n = 150) and fertile controls (n = 199) were genotyped for polymorphisms in oestrogen receptor genes ESR1 (rs2234693 - T/C single nucleotide polymorphism (SNP), dinucleotide (TA)(n) repeat) and ESR2 (dinucleotide (CA)(n) repeat), progesterone receptor gene PGR (rs10895068 - G/A SNP, 306-bp Alu-insertion), 17β-hydroxysteroid dehydrogenase type 1 gene HSD17B1 (rs605059 - A/G SNP), and aromatase gene CYP19A1 (rs10046 - C/T SNP, (TTTA)(n) tetranucleotide repeat, 3-bp TCT insertion/deletion polymorphism).
|
20586553 |
2011 |